TACSTD2 and breast carcinoma: Sacituzumab govitecan has shown a potential for greater efficacy in tumors with relatively high Trop-2 expression, and increased antitumor activity of sacituzumab govitecan has been seen in tumor xenografts derived from Trop-2-overexpressing breast cancer clones.